Recent WHO recommendations for the treatment of tuberculosis have emphasized the need for simplicity and standardization of short term chemotherapy regims which can be applied in all forms of tuberculosis, including both pulmonary and extrapulmonary forms. But in order for the recommended chemotherapy regimes to be effective, there is a need for precise organization. Patient care must begin with the first consultation, dosage must be adapted to patient weight, drug intake must, at least during the initial phase of treatment, be supervised and patients who are absent or irregular should be recalled, surveillance and correction of rare side effects should be recorded, global consideration of the patient's medical and social problems and laboratory (and clinical) check-ups at the end of the initial phase of treatment and again at the end of treatment. Together, the aim of these technical and organizational measures is the limit the development bacterial resistance both to isoniazid and to rifampicin. In countries with limited financial resources, where the majority of the tuberculosis population lives, a reliable network of laboratories equipped with microscopes and a permanent anti-tuberculosis supply organization are required for any and all treatment programmes. In all countries, the evaluation of results using representative cohorts and surveillance of bacterial resistance provide evidence that such policies are successful.
Download full-text PDF |
Source |
---|
Future Sci OA
December 2025
Gastroenterology Department, La Rabta Hospital, Tunis, Tunisia.
Background: Colonic stenosis in Crohn's disease (CD) is uncommon, and data on surgery-free survival are limited. This study aimed to determine surgery-free survival rates and identify associated factors.
Patients And Methods: A retrospective study was conducted from 2003 to 2022, including patients with CD complicated by colonic stenosis.
BMJ Open
January 2025
Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
Introduction: Non-adherence to tuberculosis (TB) treatment poses a significant challenge to effective TB management globally and is a major contributor to the emergence of multidrug-resistant TB. Although adherence to TB treatment has been widely studied, a comprehensive evaluation of the comparative levels of adherence in high- versus low-TB burden settings remains lacking. The objective of this systematic review and meta-analysis is to assess the levels of adherence to TB treatment in high-TB burden countries compared to low-burden countries.
View Article and Find Full Text PDFLancet Glob Health
January 2025
Pathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, Institut National de la Santé et de la Recherche Médicale, Montpellier, France. Electronic address:
People who use drugs show a higher incidence and prevalence of tuberculosis than people who do not use drugs in areas where Mycobacterium tuberculosis is endemic. However, this population is largely neglected in national tuberculosis programmes. Strategies for active case finding, screening, and linkage to care designed for the general population are not adapted to the needs of people who use drugs, who are stigmatised and difficult to reach.
View Article and Find Full Text PDFDiagn Microbiol Infect Dis
January 2025
National Reference Laboratory of Control and Monitoring of Antibiotic Resistance (NRL-CMAR), Department Microbiology, National Center of Infectious and Parasitic Diseases (NCIPD), 26 Yanko Sakazov Blvd., Sofia, Bulgaria.
Increased incidence of Clostridioides difficile infections were documented in Bulgarian hospitals during COVID-19. WGS was performed on 39 isolates from seven hospitals during 2015-2022. Antimicrobial resistance and toxin genes were inferred from genomes.
View Article and Find Full Text PDFTuberculosis (Edinb)
January 2025
Latvian Biomedical Research and Study Centre, Ratsupites street 1, k-1, Riga, LV-1067, Latvia; Riga Stradiņš University, Pharmacogenetic and Precision Medicine Laboratory, Konsula street 21, Riga, LV-1007, Latvia. Electronic address:
Biomarker research characterising the effect of anti-tuberculosis (TB) chemotherapy on systemic body response is still limited. In this study, we aimed to investigate fluctuations in circulating cell-free mitochondrial DNA (ccf-mtDNA) and circulating cell-free nuclear DNA (ccf-nDNA) copy number (CN) in blood plasma of patients with drug-susceptible TB (DS-TB) and to decipher factors related to these fluctuations. The results showed considerable changes in ccf-mtDNA CN in plasma samples before drug intake and 2 and 6 h afterwards, with high inter patient variability at each time point.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!